# A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients

> **NCT06557174** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.** · enrollment: 116 (estimated)

## Conditions studied

- Neuromyelitis Optica Spectrum Disorder (NMOSD)

## Interventions

- **DRUG:** IMC-002
- **DRUG:** mycophenolate mofetil， MMF

## Key facts

- **NCT ID:** NCT06557174
- **Lead sponsor:** ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10-10
- **Primary completion:** 2025-11-10
- **Final completion:** 2026-07-10
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2024-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06557174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06557174, "A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06557174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*